Markets research 01.05.2026

🌏Markets:

SPY +1.86 +0.26%(pre/m)
QQQ −0.31 −0.05%(pre/m)

🆕Economic News:

10:00 USA – ISM Manufacturing Employment
10:00 USA – ISM Manufacturing PMI

📈 Gap Ups
Reaction to earnings/guidance:

AAPL TEAM TWLO RDDT EL NVT MRNA ZETA ROKU

Other news:

AAPL approved a new buyback of up to $100 billion and increased its dividend.
VEEV Set to Join S&P 500 on May 6 / replacing $NYSE:CTRA (DVN is acquiring CTRA)
Investor sentiment across cannabis stocks improved after the U.S. Justice Department moved state-regulated marijuana toward Schedule III. AKAN delivered one of the biggest rallies in April among cannabis stocks, rocketing ~2200%
CUE Announces $30 Million Private Placement
NVDA MSFT AMZN SIGN PENTAGON AI DEALS

📉 Gap Downs
Reaction to earnings/guidance:

RBLX SMMT WDC SNDK RYAN AXTI NWG ATMU AMGN

Other news:

Morgan Stanley Downgrades ELF to Equalweight from Overweight, Lowers PT to $67 from $80

‼️Additional

Today, Trump is expected to justify to Congress the continuation of the military operation against Iran.
-- Most analysts believe Congress will give the “green light” for the continuation of hostilities.

🏢IPO

COAG – Hemab Therapeutics Holdings, Inc.
Company develops under-the-skin treatments for rare blood clotting disorders. Lead drug, sutacimig / HMB-001, has completed Phase 2 and is ready for Phase 3 in Glanzmann thrombasthenia, a rare bleeding disorder. The company also has earlier programs for Factor VII deficiency and Von Willebrand Disease. No revenue yet.
Price: $18.00
Shares: 16.8M
Raised: $301.5M
LTM:
Revenue: $0
Net Income: -$63.9M
Comparable public companies: BMRN, QURE, RARE, ALNY, NVO

SPTX – Seaport Therapeutics
Company develops oral treatments for depression, anxiety and other neuropsychiatric disorders. Its platform is designed to make existing drug mechanisms work better as pills by improving absorption and reducing side effects. Lead candidate, GlyphAllo, is being tested for major depressive disorder, with key Phase 2b data expected in 2027. Second candidate targets anxiety and sleep-related symptoms.
Price: $18.00
Shares: 14.2M
Raised: $254.9M
LTM:
Revenue: $0
Net Income: -$74.9M
Comparable public companies: SAGE, AXSM, CMPS, ATAI, GHRS

📋 List of tickers involved:
$NYSE:CTRA

Best regards – hi2morrow team.

hi2morrow_team

Trading | NYSE | NASDAQ ⚡
A community of active traders from hi2morrow
✅ Take the trading firm evaluation program: hi2morrow.com/
✅ Join the club: hi2morrow.com/club
✅ Trading academy: hi2morrow.com/course

또한 다음에서도:

면책사항

해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.

hi2morrow_team

또한 다음에서도: